Important Safety Information
Clinical use:
- Not for pediatric use
- No difference in effectiveness in geriatric patients
Contraindications:
- Hypersensitivity to avacopan or any ingredients in the formulation
Relevant warnings and precautions:
- Increased risk for cardiac disorders with certain treatment regimens
- Gastrointestinal symptoms
- Risk of hepatic injury
- Not recommended for patients with activated, untreated, and/or uncontrolled chronic liver disease
- Angioedema
- Immunization with live vaccines
- Avoid use in patients with active serious infection, including localized infections
- Obtain liver function tests before initiating treatment with TAVNEOS, and monitor every 4 weeks after start of therapy for the first 6 months of treatment and as clinically indicated thereafter
- Obtain Hepatitis B virus serology before initiating treatment
- Pregnancy
- Women of childbearing potential not using contraception
- Breast-feeding
For more information:
Please consult the Product Monograph at https://otsukacanada.com/product_monographs/TAVNEOS_EN_PM.pdf for important information relating to adverse reactions, drug interactions, and dosing that has not been discussed in this piece. The Product Monograph is also available by calling us at 1-877-341-9245.